← Leaderboards
Langdon Leforrest Miller
Ptc Therapeutics, Inc.
$1,455,058
Attributed
$1,455,058
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $896.6K · FY2006–09$1M$750K$500K$250K$0
'06
'07
'08
'09
Funding mix
By agency
FDA$956,843 · 2
NIH$498,215 · 1
By mechanism
R01$956,843 · 2
RC1$498,215 · 1
Top collaborators
No co-investigators on record.
Most similar at Ptc Therapeutics, Inc.
Same institution · by research overlap
- Jay A Barth$3,397,697
- Robert J Spiegel$399,984
Others in their field
Top investigators on “Adult”
- Lawrence Corey · Fred Hutchinson Cancer Center$594,628,824
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$397,114,680
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$388,038,550
- Judith S. Currier · University Of California Los Angeles$251,592,913
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$196,603,707
- Carol Nesel · Westat$188,148,170
Research focus
AdultAffectAnimal ModelAnimalsAreaBaseBioavailableBiological ProductsBlood Coagulation FactorCatheter Related InfectionClinical Practice GuidelineClinical TrialsCommunitiesComplicationControlled StudyCostCouplingCystic FibrosisDefectDesignDisease TransmissionDocumentationDoseAchievement
Grant awards (4)
Phase 2a Study of Ataluren in Hemophilia A and B (IND 104,321)$498,215
RC1 · FY2009 · HL · contact PI
Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (IND 68,431)$398,393
R01 · FY2009 · FD · contact PI
PHASE 2 STUDY OF PTC124 AS AN ORAL TREATMENT FOR NONSEN*$279,225
R01 · FY2007 · FD · contact PI
PHASE 2 STUDY OF PTC124 AS AN ORAL TREATMENT FOR NONSEN*$279,225
R01 · FY2006 · FD · contact PI